BIO-Europe Spring® 2017: Genentech's BD head spotlights neuroscience pipeline

April 13, 2017

Thomas Zioncheck, global head of business development for neuroscience, ophthalmology, and research tools and technology at Genentech, talks to Scrip about the company's early-stage partnering strategy and R&D goals outside of oncology. Zioncheck discusses Genentech's multiple sclerosis and Alzheimer's portfolios, therapy areas not as widely promoted as the company's active and expansive immuno-oncology pipeline. Genentech's BD head also highlights the company's early-stage development program for a novel amyotrophic lateral sclerosis (ALS) therapy, a disease that has garnered more attention since the widely-shared ALS Ice Bucket Challenge—a social media fundraising and awareness campaign. The company is developing RG6000, a dual leucine zipper kinase (DLK) inhibitor, for the treatment of ALS. The drug, a new molecular entity, is currently in Phase I trials.

 

Click here for more coverage of the activities held during BIO-Europe Spring

Previous Video
BIO-Europe Spring® 2017: TxCell plans first-in-man trial of regulatory T cells
BIO-Europe Spring® 2017: TxCell plans first-in-man trial of regulatory T cells

Having completed a Phase I/IIa study of Ovasave, a drug candidate from its first generation non-modified an...

Next Video
BIO-Europe Spring® 2017: Sofinnova chairman discusses entrepreneurial culture change in biotech
BIO-Europe Spring® 2017: Sofinnova chairman discusses entrepreneurial culture change in biotech

Antoine Papiernik is the chairman of Paris-based Sofinnova Partners, a venture capital firm that invests in...